Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Michail Ignatiadis, Christos Sotiriou, Klaus Pantel (Herausgeber)

Buch | Softcover

XIV, 254 Seiten

2014 | 2012
Springer Berlin (Verlag)
978-3-642-44587-3 (ISBN)

Artikel merken

This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

Minimal residual disease and circulating tumor cells in breast cancer: Open questions for research.- Minimal residual disease and breast cancer metastasis.- Self-seeding in cancer.- Microenvironments dictating tumor cell dormancy.- Technologies for circulating tumor cell (CTC) and disseminated tumor cell (DTC) detection and characterization.- Immunomagnetic separation technologies.- Microfluidic technologies for the isolation of CTCs.- EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients.- Advances in optical technologies for rare cell detection and characterization.- Size-based enrichment technologies for circulating tumor cell (CTC) detection and characterization.- Emerging technologies for CTC detection based on depletion of normal cells.- Molecular assays for the detection and characterization of CTCs.- Multiplex molecular analysis of CTCs.- Other blood-based biomarkers.- Circulating DNA and next generation sequencing.- Circulating microRNAs as non-invasive biomarkers in breast cancer.- Circulating endothelial cells and circulating endothelial progenitors.- Disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in breast cancer clinical research and practice.- Bone marrow DTCs.- CTCs in primary breast cancer.- CTCs in early breast cancer.- CTCs in metastatic breast cancer.- HER2-positive DTCs/CTCs in breast cancer.- DTCs and CTCs in breast cancer - 5 decades later.- Drug and circulating tumor cell co-development.- Challenges in drug and biomarker co-development.- Challenges and opportunities in the use of CTCs for companion diagnostic development.

lt;p>From the reviews:

"This book is aimed directly at cancer researchers, delving into the various technologies used to identify and characterize these rare tumor cells. ... this is the first book to summarize the progress in this field. It charts the evolution in thinking about breast cancer from the Halstedian notion of a local disease to more of a systemic illness in an accessible way and nicely summarizes the data without overwhelming readers." (Megan E. Sullivan, Doody's Review Service, July, 2012)

Erscheint lt. Verlag	9.5.2014
Reihe/Serie	Recent Results in Cancer Research
Zusatzinfo	XIV, 254 p.
Verlagsort	Berlin
Sprache	englisch
Maße	155 x 235 mm
Gewicht	415 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Gynäkologie / Geburtshilfe
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Studium ► 2. Studienabschnitt (Klinik) ► Pathologie
Schlagworte	Breast Cancer • Circulating nucleic acids • Circulating tumor cells • Micrometastasis • minimal residual disease • surgical oncology
ISBN-10	3-642-44587-X / 364244587X
ISBN-13	978-3-642-44587-3 / 9783642445873
Zustand	Neuware